The firm’s new office spans an space of 100,000 sq. ft and options labs for its current enterprise traces, which cater to numerous industries.
| Photo Credit: Special Arrangement
German specialty chemical substances main Evonik has introduced the opening of its R&D hub and new office in Thane close to Mumbai, marking the start of a new chapter for the corporate in India.
“The Evonik India Research Hub (EIRH), as it will be called, marks a significant milestone in Evonik’s development journey in India and underscores the company’s unwavering commitment to further growth in the Indian market,” Evonik India stated in a press release.
“It will be dedicated to advancing solutions that contribute to sustainability,” it added.
The firm’s new office spans an space of 100,000 sq. ft and options labs for its current enterprise traces, which cater to numerous industries.
These embrace pharmaceutical, oral care, private care, meals, feed, agriculture, tyre, rubber, plastics, oil & fuel, batteries, steel & ceramics, electronics, toners, paper, adhesives & sealants, residence care, paint & coatings, printing inks, building, emulsion, textiles, metalworking fluid and compounding.
New labs will even be began this yr, offering clients with proximity to industries related to bio-surfactants, pores and skin and hair merchandise, automotive, furnishings and mattress purposes, the corporate stated.
The firm presently employs roughly 850 staff in India in its three entities. With the opening of EIRH, it’s planning to create extra jobs for its new labs and associated operations.
Its manufacturing websites are positioned in Maharashtra and Gujarat.
Vinod Paremal, President and Managing Director, Evonik India stated, “We believe that our new office will not only facilitate greater collaboration and synergy among our team members but will also enable us to better meet the evolving needs of our customers and partners.”
Evonik operates in additional than 100 nations worldwide and generated gross sales of €15.3 billion and an working revenue (adjusted EBITDA) of €1.66 billion in 2023.
